{"id":"W4320914765","doi":"10.21203/rs.3.rs-2521809/v1","title":"Neoadjuvant chemotherapy for triple negative and Her2+ve breast cancer: striving for the standard of care","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Breast cancer; Internal medicine; Triple-negative breast cancer; Oncology; Trastuzumab; Stage (stratigraphy); Logistic regression; Cohort; Disease; Neoadjuvant therapy; Chemotherapy; Population; Odds ratio; Cancer; Retrospective cohort study; Adjuvant therapy; Medical record","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004595479,0.0002028635,0.0005379956,0.0002685809,0.0002150357,0.001593816,0.00032902,0.0006016636,0.002735884],"category_scores_gemma":[0.009112366,0.000130827,0.0002314246,0.0006648213,0.0005453569,0.001182711,0.0004744756,0.001236324,0.0007051041],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009750968,"about_ca_system_score_gemma":0.002372583,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001372763,"about_ca_topic_score_gemma":0.002314817,"domain_scores_codex":[0.9986407,0.0008755057,0.00006603299,0.00005875393,0.0003091664,0.00004977501],"domain_scores_gemma":[0.997707,0.001178897,0.0003564526,0.000289582,0.0002733092,0.0001946802],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004630366,0.000511764,0.03839014,0.001692352,0.000348851,0.000464226,0.0002759002,0.002117878,0.01146444,0.04681598,0.1004161,0.7928721],"study_design_scores_gemma":[0.001421415,0.002781131,0.2357917,0.002715273,0.0008188387,0.004721425,0.00160321,0.009768827,0.03117324,0.3048166,0.4042496,0.0001387528],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"protocol","genre_scores_codex":[0.3070318,0.1869208,0.05959133,0.3513276,0.00768369,0.000306663,0.003110518,0.0005244301,0.08350319],"genre_scores_gemma":[0.7709139,0.1142618,0.07546011,0.01658214,0.003876642,0.000352199,0.002246502,0.0003556994,0.015951],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.004595479,"threshold_uncertainty_score":0.0243035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04324943760974316,"score_gpt":0.4014099927418728,"score_spread":0.3581605551321296,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}